Loss of PTEN occurs at high frequency in high-grade and metastatic CaP and is accompanied by constitutive activation of AKT [8], attesting to the critical role AKT plays in prostate carcinogenesis [9], [10]. The gene discussed is AKT1; the disease is medical procedure.